银屑病与生物制剂治疗时代前后心肌梗死风险:一项基于人群的随访研究
丹麦全国性前瞻性登记队列研究显示,与一般人群相比,医院诊断银屑病患者心肌梗死风险在生物制剂引入前后两个时代均持续升高:早期队列HR 1.40(95%CI 1.09-1.80),晚期队列HR 1.39(95%CI 1.10-1.75),调整教育水平和心血管药物使用后风险比未见明显改变。
要点
- 医院诊断银屑病患者心肌梗死风险较一般人群升高,早期HR 1.40(95%CI 1.09-1.80)。
- 晚期队列(生物制剂时代)HR 1.39(95%CI 1.10-1.75),风险升高未见下降。
- 早期队列银屑病患者5年累积心肌梗死发生率为2.5%,晚期队列为2.2%。
核心结论
- 医院诊断银屑病患者心肌梗死风险相对于一般人群升高,在心血管病预防关注增加和生物制剂可及的最初年份内保持不变。
研究设计与样本
- 丹麦全国性基于人群登记的前瞻性收集数据队列研究。
- 早期队列纳入1995年至2002年间首次医院诊断银屑病患者,晚期队列纳入2006年至2013年间诊断者。
- 一般人群对照按性别和出生年以10:1匹配。
- 早期队列随访至2002年1月1日,晚期队列随访至2013年1月1日。
- 早期队列银屑病4302例、一般人群43791例;晚期队列银屑病4577例(4%接受生物制剂治疗)、一般人群46376例。
主要发现
- 早期队列银屑病患者5年累积心肌梗死发生率为2.5%,晚期队列为2.2%。
- 调整教育水平和心血管药物使用后,早期队列银屑病与一般人群比较HR 1.40(95%CI 1.09-1.80)。
- 晚期队列银屑病与一般人群比较HR 1.39(95%CI 1.10-1.75)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Attention towards cardiovascular disease prevention in patients with moderate to severe psoriasis increased with the introduction of biological therapy. OBJECTIVE: To determine the risk of myocardial infarction (MI) following hospital-diagnosed psoriasis compared with the general population, in eras before and following the introduction of biological therapy. METHODS: We conducted a cohort study in Denmark utilising nationwide prospectively collected data from population-based registries. For the early era cohort, we identified subjects with first time hospital-diagnosed psoriasis between 1995 and 2002, and, for the late era cohort, those diagnosed between 2006 and 2013. Comparison cohorts from the general population were matched (10:1) on sex and birth year. All individuals were followed from date of psoriasis diagnosis (index date for matched controls) until incidence of MI, death, emigration or end of study (1 January 2002 for the early era cohort; 1 January 2013 for the late era cohort). We computed the cumulative MI incidence at 5 years of follow-up, and used Cox regression to compute HRs of MI comparing psoriasis subjects with general population subjects. RESULTS: For the early era, we identified 4302 psoriatic subjects and 43 791 general population subjects; and for the late era, 4577 psoriatic subjects (4% received biologic therapy) and 46 376 general population subjects. The cumulative incidence of MI among psoriatic subjects in the early era was 2.5% and it was 2.2% in the late era. The HRs comparing MI risk in the psoriasis and general population cohorts were 1.40 (95% CI: 1.09-1.80), for the early era, and 1.39 (95% CI: 1.10-1.75) for the late era, adjusting for educational level and use of cardiovascular drugs. CONCLUSION: The increased risk of MI among patients with hospital-diagnosed psoriasis, relative to the general population, remained unchanged during the initial years of increased attention towards cardiovascular disease prevention and availability of biologic therapy.
引用
- Leisner MZ, Lindorff Riis J, Gniadecki R, et al. Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study. J Eur Acad Dermatol Venereol. 2018. PMID: 29719939. doi:10.1111/jdv.15021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。